BMS-181156

BMS-181156 is an experimental small molecule compound belonging to the class of retrochalcones—organic compounds structurally related to chalcones but lacking oxygen functionalities at the C2'- and C6'-positions. Its chemical formula is C24H26O3 and it has a molecular weight of approximately 362.46 g/mol[1][4]. The compound was developed as a drug candidate by Bristol Myers Squibb but has not been approved for any indication and does not appear to have advanced beyond preclinical or very early clinical development. No marketed formulations or brand names are associated with this agent[1][7]. Its mechanism of action and therapeutic targets have not been publicly disclosed.

Other names

(E)-4-(3-Oxo-3-(5,6,7,8-tetrahydro-5,5,8,8-tetramethyl-2-naphthalenyl)-1-propenyl)benzoic acidBENZOIC ACID 4-((1E)-3-OXO-3-(5,6,7,8-TETRAHYDRO-5,5,8,8-TETRAMETHYL-2-NAPHTHALENYL)-1-PROPEN-1-YL)110368-35-9